Securities code: Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) stock abbreviation: Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) No.: Lin 2022039 bond Code: 143422 bond abbreviation: 18 Fuyao 01
Bond Code: 155067 bond abbreviation: 18 Fuyao 02
Bond Code: 175708 bond abbreviation: 21 Fuyao 01
Shanghai Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) (Group) Co., Ltd
The resolution of the first meeting (regular meeting) of the eighth board of supervisors in 2022 announced that the board of supervisors and all supervisors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and integrity of its contents.
The first meeting (regular meeting) of the 8th board of supervisors of Shanghai Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) (Group) Co., Ltd. (hereinafter referred to as “the company”) in 2022 was held by means of communication (video conference) on March 22, 2022. There were 3 supervisors who should be present and 3 actually present. The meeting was presided over by Ms. Ren Qian, chairman of the board of supervisors of the company. The articles of association of the people’s Republic of China (hereinafter referred to as the “articles of association”) and other relevant laws and regulations of the people’s Republic of China (hereinafter referred to as the “articles of association”). The meeting considered and adopted the following resolutions:
1、 The annual report of the group (i.e. the company and its holding subsidiaries / units, the same below) for 2021 was reviewed and approved. Agree to prepare the full text and summary of the group’s 2021 annual report in accordance with the requirements of relevant laws and regulations in China. Agree to prepare the group’s 2021 annual report (and its corporate governance report and ESG report) and performance announcement in accordance with the requirements of the Securities Listing Rules of the stock exchange of Hong Kong Limited.
After review, the 8th board of supervisors issued the following audit opinions on the 2021 annual report of the group:
1. The preparation and review procedures of the group’s 2021 annual report comply with laws, regulations, the articles of association and the provisions of the company’s internal management system;
2. The content and format of the group’s 2021 annual report comply with the provisions of the China Securities Regulatory Commission (hereinafter referred to as the “CSRC”), the Shanghai Stock Exchange (hereinafter referred to as the “SSE”) and the stock exchange of Hong Kong Limited, and the information contained can truly reflect the group’s operation and financial status in 2021 from all aspects;
3. The board of supervisors did not find that the personnel involved in the preparation and deliberation of the report violated the confidentiality provisions.
Voting results: 3 in favor, 0 against and 0 abstention.
The 2021 annual report of the group needs to be submitted to the general meeting of shareholders of the company for deliberation.
The full text and summary of the group’s 2021 annual report prepared in accordance with relevant laws and regulations in China are detailed on the website of Shanghai Stock Exchange（ http://www.sse.com.cn. ）。
2、 Deliberated and adopted the work report of the board of supervisors in 2021.
Voting results: 3 in favor, 0 against and 0 abstention.
This report shall also be submitted to the general meeting of shareholders of the company for deliberation.
3、 Deliberated and adopted the 2021 annual internal control evaluation report.
Voting results: 3 in favor, 0 against and 0 abstention.
See the website of Shanghai stock exchange for the internal control evaluation report in 2021（ http://www.sse.com.cn. ）。 4、 The special report on the deposit and actual use of raised funds in 2021 was reviewed and adopted.
Voting results: 3 in favor, 0 against and 0 abstention.
See the website of Shanghai stock exchange for the special report on the deposit and actual use of raised funds in 2021（ http://www.sse.com.cn. ）。
5、 The proposal on the provision for asset impairment in 2021 was reviewed and approved.
After review, the 8th board of supervisors considered that the provision for asset impairment was in line with the accounting standards for Business Enterprises No. 8 – asset impairment issued by the Ministry of finance of the people’s Republic of China, the accounting supervision risk prompt No. 8 – goodwill impairment issued by the CSRC and the relevant accounting policies of the company, and the basis was sufficient; The review procedure complies with the provisions of relevant laws and regulations and the articles of association.
Voting results: 3 in favor, 0 against and 0 abstention.
For details, please refer to the announcement on the provision for asset impairment issued on the same day.
It is hereby announced.
Board of supervisors of Shanghai Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) (Group) Co., Ltd. March 22, 2002
